Oncology Business Management

Physicians tend to agree that the practice of defensive medicine is widespread, especially in oncology where much more is at stake than in the general practitioner's office. However, things can go drastically wrong.

The pace of consolidation shows no sign of slowing down, and this trend also applies to oncology, as more and more community-based oncology practices are joining large health systems.

The FDA granted the selective tropomyosin receptor kinase inhibitor LOXO-101 a breakthrough therapy designation for the treatment of adult or pediatric patients with unresectable or metastatic solid tumors with NTRK-infusion proteins who progressed on prior therapy or have no other available treatment options.

The statistics show you are much more likely to encounter an independent oncology practice in Alaska than in New Hampshire.

The Centers for Medicare & Medicaid Services is wavering on its commitment to the Medicare reform package passed in 2015, based on widespread concerns that the changes may be unwieldy and could increase the pace at which smaller physician practices are being forced into mergers.

Pressures on independent oncology practices have been mounting for years, as payer data-reporting requirements become more onerous and revenue from drug reimbursements decline.

Many oncology practices were motivated to join the Oncology Care Model in order to keep up with the evolution of value-based care. But when the Center for Medicare & Medicaid Innovation started telling practices that their applications had been accepted, it was panic time for some.

Ventura County Hematology Oncology Specialists opened its doors 45 years ago and has long occupied a comfortable niche in its local market.

COTA Inc, an independent health care informatics company was founded to build research-grade, real-world data to exponentially improve outcomes and reduce costs—ensuring the right care for the right patient every time.

The FDA has issued two draft guidances that will provide regulatory oversight for the use of next-generation sequencing-based tests.

The FDA has granted a breakthrough therapy designation to ibrutinib has a potential treatment for patients with chronic graft-versus-host-disease after failure of one or more lines of systemic therapy.

A year after announcing its intention to launch the Oncology Care Model alternative payment plan for oncology care, The Centers for Medicare & Medicaid Services said it has 196 practices enrolled across the United States and that the official start date is Friday, July 1.

Richard Pazdur, MD, has been named the acting director of the FDA's newly created Oncology Center of Excellence, which is aimed to expedite the development of novel combination products and support an integrated approach to oncology research.

Members of the Pediatric Subcommittee of the FDA's Oncologic Drugs Advisory Committee voiced their support for new clinical trials examining promising cancer agents in pediatric patients.